Achieve Life Sciences is trading lower amid biotech sector weakness, at $6.27 (-10.04%).
- XBI fell 2.06% during the regular session; the S&P 500 was down 0.58% and Nasdaq 1.30%.
- No new company-specific announcement explaining the October 16 decline surfaced in the search. Achieve’s FDA letter concerned manufacturing and labeling, with a fourth-quarter 2026 resubmission planned; it does not establish a fresh catalyst for this session.